CytomX Therapeutics’ (CTMX) Neutral Rating Reiterated at HC Wainwright

CytomX Therapeutics (NASDAQ:CTMX)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX opened at $1.14 on Tuesday. The firm has a market capitalization of $89.22 million, a PE ratio of 6.71 and a beta of 1.03. The business has a 50 day simple moving average of $1.06 and a two-hundred day simple moving average of $1.17. CytomX Therapeutics has a 1 year low of $0.83 and a 1 year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. The company had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same quarter in the previous year, the business earned $0.04 EPS. Equities research analysts expect that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CTMX. US Bancorp DE bought a new position in CytomX Therapeutics in the 3rd quarter worth about $40,000. XTX Topco Ltd boosted its holdings in shares of CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 48,033 shares during the period. Forefront Analytics LLC grew its stake in CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 43,176 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in CytomX Therapeutics during the 3rd quarter worth $104,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.